| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Philip D Harve. The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatric disease and treatment. vol 11. 2015-05-21. PMID:25995636. |
lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the united kingdom, other european countries, the united states, and canada. |
2015-05-21 |
2023-08-13 |
Not clear |
| Philip D Harve. The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatric disease and treatment. vol 11. 2015-05-21. PMID:25995636. |
long-term treatment of schizophrenia with lurasidone has been shown to reduce the risk of relapse in patients with schizophrenia. |
2015-05-21 |
2023-08-13 |
Not clear |
| Philip D Harve. The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatric disease and treatment. vol 11. 2015-05-21. PMID:25995636. |
a significant evidence base supports the use of lurasidone as a promising agent for the treatment of schizophrenia. |
2015-05-21 |
2023-08-13 |
Not clear |
| Jyotsana R Madan, Kiran T Pawar, Kamal Du. Solubility enhancement studies on lurasidone hydrochloride using mixed hydrotropy. International journal of pharmaceutical investigation. vol 5. issue 2. 2015-04-03. PMID:25838997. |
lurasidone hcl (lrd) is an antipsychotic agent specially used in the treatments of schizophrenia and is a good example of the problems associated with low aqueous solubility. |
2015-04-03 |
2023-08-13 |
Not clear |
| Jyotsana R Madan, Kiran T Pawar, Kamal Du. Solubility enhancement studies on lurasidone hydrochloride using mixed hydrotropy. International journal of pharmaceutical investigation. vol 5. issue 2. 2015-04-03. PMID:25838997. |
lurasidone is practically insoluble in water, has poor bioavailability and slow onset of action and therefore cannot be given in emergency clinical situations like schizophrenia. |
2015-04-03 |
2023-08-13 |
Not clear |
| Cecilio Alamo, Francisco López-Muñoz, Pilar García-Garcí. The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder. Expert review of neurotherapeutics. vol 14. issue 6. 2015-01-13. PMID:24779382. |
lurasidone was approved in 2010 for the treatment of schizophrenia and recently, 2013, for bipolar depression in monotherapy and an adjunct to lithium or valproate. |
2015-01-13 |
2023-08-13 |
Not clear |
| A Luoni, A Berry, F Calabrese, S Capoccia, V Bellisario, P Gass, F Cirulli, M A Riv. Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 6. 2014-12-16. PMID:24440552. |
to address this point, we treated rats during adolescence with the multi-receptor antipsychotic lurasidone, which was proven to be effective in animal models of schizophrenia. |
2014-12-16 |
2023-08-12 |
rat |
| Young Sup Woo, Hee Ryung Wang, Won-Myong Bah. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatric disease and treatment. vol 9. 2014-06-24. PMID:24143101. |
lurasidone is a benzisothiazol derivative and an atypical antipsychotic approved by the us food and drug administration for the acute treatment of adults with schizophrenia (october 2010) and bipolar 1 depression (june 2013). |
2014-06-24 |
2023-08-12 |
Not clear |
| Philip D Harvey, Cynthia O Siu, Jay Hsu, Josephine Cucchiaro, Paul Maruff, Antony Loebe. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 23. issue 11. 2014-06-17. PMID:24035633. |
effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. |
2014-06-17 |
2023-08-12 |
human |
| Philip D Harvey, Cynthia O Siu, Jay Hsu, Josephine Cucchiaro, Paul Maruff, Antony Loebe. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 23. issue 11. 2014-06-17. PMID:24035633. |
this double-blind study evaluated change in cognitive performance and functional capacity in lurasidone and quetiapine xr-treated schizophrenia patients over a 6-week, placebo-controlled study, followed by a 6-month, double-blind extension. |
2014-06-17 |
2023-08-12 |
human |
| Steven G Potkin, David B Keator, Marilyn L Kesler-West, Dana D Nguyen, Theo G M van Erp, Jogeshwar Mukherjee, Nikunj Shah, Adrian Pred. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS spectrums. vol 19. issue 2. 2014-06-03. PMID:24073841. |
d2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. |
2014-06-03 |
2023-08-12 |
Not clear |
| Steven G Potkin, David B Keator, Marilyn L Kesler-West, Dana D Nguyen, Theo G M van Erp, Jogeshwar Mukherjee, Nikunj Shah, Adrian Pred. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS spectrums. vol 19. issue 2. 2014-06-03. PMID:24073841. |
objective/introduction: lurasidone is an atypical antipsychotic medication approved for the treatment of schizophrenia over a dose range of 40-160 mg/day. |
2014-06-03 |
2023-08-12 |
Not clear |
| Steven G Potkin, David B Keator, Marilyn L Kesler-West, Dana D Nguyen, Theo G M van Erp, Jogeshwar Mukherjee, Nikunj Shah, Adrian Pred. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS spectrums. vol 19. issue 2. 2014-06-03. PMID:24073841. |
this study examined d2 receptor occupancy and its association with clinical improvement and side effects in patients with schizophrenia or schizoaffective disorder following repeated doses of 80, 120, or 160 mg/day of lurasidone. |
2014-06-03 |
2023-08-12 |
Not clear |
| Antony D Loebel, Cynthia O Siu, Josephine B Cucchiaro, Andrei A Pikalov, Philip D Harve. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS spectrums. vol 19. issue 2. 2014-06-03. PMID:24330860. |
daytime sleepiness associated with lurasidone and quetiapine xr: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. |
2014-06-03 |
2023-08-12 |
Not clear |
| Antony D Loebel, Cynthia O Siu, Josephine B Cucchiaro, Andrei A Pikalov, Philip D Harve. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS spectrums. vol 19. issue 2. 2014-06-03. PMID:24330860. |
the aim of this analysis was to compare the effects of 2 atypical antipsychotic agents, lurasidone (80 mg/d or 160 mg/d) and quetiapine xr (600 mg/d), on daytime alertness, and to evaluate the effects of daytime sleepiness on treatment outcomes in patients with an acute exacerbation of schizophrenia. |
2014-06-03 |
2023-08-12 |
Not clear |
| Frank I Tarazi, Marco A Riv. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Expert opinion on drug discovery. vol 8. issue 10. 2014-04-11. PMID:23837554. |
the preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. |
2014-04-11 |
2023-08-12 |
Not clear |
| Frank I Tarazi, Marco A Riv. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Expert opinion on drug discovery. vol 8. issue 10. 2014-04-11. PMID:23837554. |
lurasidone is a novel antipsychotic drug approved for the treatment of schizophrenia in adults. |
2014-04-11 |
2023-08-12 |
Not clear |
| Krithika Rajagopalan, Ken O'Day, Kellie Meyer, Andrei Pikalov, Antony Loebe. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release. Journal of medical economics. vol 16. issue 8. 2014-04-07. PMID:23742620. |
annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release. |
2014-04-07 |
2023-08-12 |
Not clear |
| Krithika Rajagopalan, Ken O'Day, Kellie Meyer, Andrei Pikalov, Antony Loebe. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release. Journal of medical economics. vol 16. issue 8. 2014-04-07. PMID:23742620. |
to model the economic impact of annual relapses/relapse-related hospitalizations among adults with schizophrenia treated with lurasidone or quetiapine extended-release (xr). |
2014-04-07 |
2023-08-12 |
Not clear |
| Dean F Wong, Hiroto Kuwabara, James Robert Brašić, Thomas Stock, Atul Maini, Emily G Gean, Antony Loebe. Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology. vol 229. issue 2. 2014-03-31. PMID:23649882. |
a positron emission tomography (pet) study of dopamine d₂ receptor occupancy was conducted to support a rational dose selection for clinical efficacy studies with lurasidone, an atypical antipsychotic that was approved for the treatment of schizophrenia by the fda in late 2010. |
2014-03-31 |
2023-08-12 |
human |